Background Little is known about generalisability of randomised controlled trials (RCTs) for
idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Placebo arms of clinical trials provide an opportunity to investigate the natural history of
idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life …

Idiopathic pulmonary fibrosis (IPF) is a dreadful disease that lacks adequate therapy. A
number of treatment trials have been performed and have utilized a variety of primary …

After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in
2011, we investigated clinical management practices for patients with IPF according to …

Introduction: While many pharmacologic therapies for the treatment of idiopathic pulmonary
fibrosis (IPF) have been evaluated via randomized, placebo-controlled clinical trials (RCTs) …

Rationale: Several predictors of mortality in patients with idiopathic pulmonary fibrosis have
been described; however, there is a need for a practical and accurate method of quantifying …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …

Background Most data on outcomes in Idiopathic Pulmonary Fibrosis (IPF) pre-dates current
guidelines. Data on rates of infection is sparse; the effect of low-dose corticosteroids and …